PE20081895A1 - Regimen anticonceptivo oral - Google Patents

Regimen anticonceptivo oral

Info

Publication number
PE20081895A1
PE20081895A1 PE2008000538A PE2008000538A PE20081895A1 PE 20081895 A1 PE20081895 A1 PE 20081895A1 PE 2008000538 A PE2008000538 A PE 2008000538A PE 2008000538 A PE2008000538 A PE 2008000538A PE 20081895 A1 PE20081895 A1 PE 20081895A1
Authority
PE
Peru
Prior art keywords
oral contraceptive
hormone
refers
regime
days
Prior art date
Application number
PE2008000538A
Other languages
English (en)
Inventor
Jean-Louis Thomas
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of PE20081895A1 publication Critical patent/PE20081895A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE TIPO HORMONAL EN FORMA DE COMPRIMIDO QUE CONTIENE: A) 1,5MG DE 17-BETA-ESTRADIOL; Y B) 2,5MG DE ACETATO DE NOMEGESTROL. SE REFIERE TAMBIEN A UN METODO MONOFASICO PARA LA ANTICONCEPCION QUE CONSISTE EN ADMINISTRAR ORALMENTE DICHA COMPOSICION POR UN PERIODO DE 24 DIAS SEGUIDO DE UN PERIODO LIBRE DE HORMONAS DE 4 DIAS EN LOS CUALES SE ADMINISTRA DIARIAMENTE UN PLACEBO
PE2008000538A 2007-03-26 2008-03-25 Regimen anticonceptivo oral PE20081895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92032607P 2007-03-26 2007-03-26

Publications (1)

Publication Number Publication Date
PE20081895A1 true PE20081895A1 (es) 2009-01-26

Family

ID=39672648

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000538A PE20081895A1 (es) 2007-03-26 2008-03-25 Regimen anticonceptivo oral

Country Status (10)

Country Link
US (1) US20080242650A1 (es)
AR (1) AR065816A1 (es)
AU (1) AU2008231744A1 (es)
BR (1) BRPI0809089A2 (es)
CA (1) CA2682049A1 (es)
CL (1) CL2008000866A1 (es)
MX (1) MX2009010320A (es)
PE (1) PE20081895A1 (es)
TW (1) TWI472332B (es)
WO (1) WO2008116873A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
TW200930343A (en) * 2007-09-21 2009-07-16 Organon Nv Drug delivery system
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
US9198876B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
CA2740004A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
US10596103B2 (en) 2013-12-11 2020-03-24 Merek Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
JPS61243059A (ja) * 1985-04-19 1986-10-29 Konishi Kagaku Kogyo Kk 高純度４，４′−ジヒドロキシジフエニルスルホンの製造法
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5565449A (en) * 1991-10-18 1996-10-15 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
FR2737411B1 (fr) * 1995-08-01 1997-10-17 Theramex Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
FR2754179B1 (fr) * 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
EP1568688B1 (en) * 2002-11-25 2011-08-31 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient

Also Published As

Publication number Publication date
TW200902031A (en) 2009-01-16
CL2008000866A1 (es) 2008-10-03
AU2008231744A1 (en) 2008-10-02
WO2008116873A1 (en) 2008-10-02
AR065816A1 (es) 2009-07-01
US20080242650A1 (en) 2008-10-02
CA2682049A1 (en) 2008-10-02
MX2009010320A (es) 2010-01-20
TWI472332B (zh) 2015-02-11
BRPI0809089A2 (pt) 2014-09-09

Similar Documents

Publication Publication Date Title
PE20081895A1 (es) Regimen anticonceptivo oral
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
PE20070329A1 (es) Composiciones con estrogenos y metodos terapeuticos para su uso
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
BRPI0514180A (pt) composto, composição farmacêutica, uso de um composto, kit farmaceuticamente útil adaptado para administração oral diária, e, métodos de preparação de um composto, e de contracepção em um mamìfero
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
PE20140854A1 (es) Formas de dosificacion farmaceutica
CO6400186A2 (es) Tabletas de acetato de ulipristal
BRPI0516238A (pt) composição farmacêutica contendo diclofenaco
BR122017015098B8 (pt) formulações farmacêuticas de liberação imediata que contêm hidrato de propileno glicol de dapagliflozina
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
ES2693085T1 (es) Uso de estriol en bajas dosis
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
JP2010535767A5 (es)
MX2010001839A (es) Metodo y aparato para comunicacion y metodo y aparato para controlar comunicacion.
PE20081799A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
PE20090625A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
AR065971A1 (es) Nuevo regimen de drosperinona/17beta-estradiol, producto farmaceutica combinado y conjunto de elementos (kit) para su aplicacion
ES2574999T3 (es) Método para la contracepción a demanda usando levonorgestrel o norgestrel
UY30315A1 (es) Formulacion de medicamento liquida
HN2010001775A (es) Composicion farmaceutica oral que comprende la combinacion de una sal de keterolaco y vitaminas del complejo b

Legal Events

Date Code Title Description
FA Abandonment or withdrawal